09 June 2000
PROFESSIONAL SERVICES and CONFIDENTIALITY
AGREEMENT between
Lexon, Inc.
&
DIAGNOSTIC ONCOLOGY CRO, Inc.
PARTIES
The parties to this Professional Services and Confidentiality Agreement are
Lexon, Inc. and its affiliates, subsidiaries and the like ("LEXON") located in
Tulsa, Oklahoma, and DIAGNOSTIC ONCOLOGY CRO, Inc. ("DOCRO"), located in
Seymour, Connecticut.
PURPOSES
LEXON is engaged in the business of developing medical diagnostic products for
distribution to the biotechnology, healthcare, medical diagnostic, medical
device, and therapeutic industries, in particular, in vitro diagnostic assays
for determining the presence of telomerase in the blood, other body fluids, and
other specimen matrices of mammals.
DOCRO is engaged in providing technology assessment, technology development, and
laboratory and clinical trial services to medical device developers, in
particular, providing technology assessment and technology development services
related to the development and commercialization of in vitro diagnostic assays
for determining the amount of tumor markers or other analytes in the tissues,
blood, other fluids, and other specimen matrices of mammals.
LEXON wishes to engage DOCRO to conduct a technology assessment and development
program for LEXON's telomerase tumor marker technology. This program requires
DOCRO to assess the current technical and clinical performance of the existing
telomerase reagents as provided by Dr. H. E. ▇▇▇▇▇▇▇▇▇, University of Maryland,
Baltimore, then for DOCRO to develop or procure purified telomerase antigens
(including various peptides and, if possible, native and recombinant protein,
for known forms of telomerase protein/nucleic acid complex) expressed in humans
and then to raise or procure a variety of monoclonal antibodies and polyclonal
antibodies to these various antigens to determine if any telomerase antigen is
overexpressed in the tissue, blood, other body fluids, and other specimen
matrices from humans diagnosed with lung or other cancers when compared to
similar specimens from apparently healthy, normal humans and
--1 of 14--
from a variety of humans diagnosed with other non-malignant diseases. Further,
if a telomerase antigen is determined by DOCRO to be overexpressed in malignant
disease and not in non-malignant disease or apparently healthy normals and LEXON
agrees, DOCRO shall develop an enzyme immunoassay for such telomerase antigen to
confirm the results in the blood or other fluid specimen matrix of a
statistically significant number (maximum of 400) patients.
In consideration of the mutual promises specified below, DOCRO offers to provide
technology assessment and technology development professional services to LEXON
in accordance with the terms and conditions of this Agreement, which LEXON
accepts.
DEFINITIONS
"Confidential & Proprietary Information" shall include any information owned by
any party, as well as information developed by DOCRO in connection with services
performed under this Agreement which shall be considered LEXON's confidential
information, whether or not such information is in oral, written or other form,
or was denominated or specifically identified as confidential when disclosed,
observed or developed. Such information may include, but is not limited to
commercial or technological plans, customer lists, discoveries, inventions,
know-how, processes, software, suppliers, trade secrets, as well as any
analytical chemical or biological specimens or prototypes.
"DOCRO" shall mean the entity identified in the PARTIES section, including any
entities affiliated with DOCRO, including but not limited to DOCRO's employees,
agents, officers or principals, and, its contractors.
"LEXON" shall mean the entity identified in the PARTIES section, including any
entities affiliated with LEXON (or any purchaser of substantially all of LEXON's
assets), including but not limited to LEXON's employees, agents, officers or
principals, and, its contractors.
"PRODUCTS" shall mean LEXON's telomerase technology used for the assessment
and/or development of an in vitro diagnostic assay to determine if any
telomerase antigen is overexpressed in the tissue, blood, other body fluids, and
other specimen matrices from humans diagnosed with lung or other cancers when
compared to similar specimens from apparently healthy, normal humans and from a
variety of humans diagnosed with other non-malignant diseases, including any
native or recombinant telomerase protein or peptide antigen in any form, and
antibody raised to any native or recombinant telomerase protein or peptide
antigen.
--2 of 14--
TERMS AND CONDITIONS
1.0 Services to be Provided by DOCRO
1.1. Technology Assessment - DOCRO shall assess for LEXON the current technical
and clinical performance of the existing telomerase reagents as provided by
LEXON and the inventor, Dr. H. E. ▇▇▇▇▇▇▇▇▇, University of Maryland, Baltimore.
1.2. Technology Development -DOCRO shall develop or procure purified telomerase
antigens (including various peptides and, if possible, native and recombinant
protein, for known forms of telomerase protein/nucleic acid complex) expressed
in humans and then to raise or procure a variety of monoclonal antibodies and
polyclonal antibodies to these various antigens to determine if any telomerase
antigen is overexpressed in the tissue, blood, other body fluids, and other
specimen matrices from humans diagnosed with lung or other cancers when compared
to similar specimens from apparently healthy, normal humans and from a variety
of humans diagnosed with other non-malignant diseases. Further, if a telomerase
antigen is determined by DOCRO to be overexpressed in malignant disease and not
in non-malignant disease or apparently healthy normals and LEXON agrees, DOCRO
shall develop an enzyme immunoassay for such telomerase antigen to confirm the
results in the blood or other fluid specimen matrix of a statistically
significant number (maximum of 400) patients.
1.3. Analysis and Reports - DOCRO shall provide to LEXON an analysis and written
report of the work performed with recommendations for the next steps to be taken
by DOCRO conducted in Section 1.1. and Section 1.2. on a bi-weekly basis from
the inception of the project. LEXON must provide written notification to DOCRO
within forty-eight (48) hours of the issuance of the report if LEXON desires
DOCRO not to perform the work that DOCRO recommends in the report. DOCRO shall
provide to LEXON a written report summarizing DOCRO's findings and activities
upon DOCRO's completion of the technology assessment portion of this Agreement
and upon termination of this Agreement.
1.4. The parties agree that DOCRO shall provide LEXON with its services under
this Agreement on a non-exclusive basis. Subject to the limitations of this
Agreement, DOCRO and LEXON may provide or obtain consulting and advisory
services to or from any third party.
1.5. Pursuant to the terms of this Agreement, DOCRO shall commence work
immediately upon receipt of a fully executed original of this Agreement and the
initial moneys set forth herein.
2.0 Term
2.1. The term of this Agreement shall commence on 09 June 2000, and shall
continue for a duration of two (2) years, but after DOCRO's completion of the
technology assessment portion of this Agreement may be terminated at will by
LEXON giving thirty (30) days written notice to
--3 of 14--
the other. In the event of such termination, LEXON's sole obligation to DOCRO
shall be to pay DOCRO any fees and expenses for services either (i) rendered by
the date of termination including any and all non-refundable prepayments made by
LEXON to DOCRO according to the terms of this Agreement or (ii) at least
partially rendered and committed with respect to any case report from an
investigator working for DOCRO.
2.2. The confidentiality provision of Section 4.0 of this Agreement shall be in
force for a period of three (3) years from the effective date of this Agreement.
3.0 Compensation & Reimbursement
3.1. DOCRO shall be compensated by LEXON according to the terms of the attached
schedule (see Attachment A. - Estimated Fees, Milestone and Payment Schedule)
and this Section 3.0 for the conduct of the technology assessment and technology
development professional services rendered by DOCRO under the provisions of this
Agreement.
3.3. DOCRO shall be compensated by LEXON for the conduct of the technology
assessment and technology development professional services in total of one
million, eight hundred, fifty-eight thousand, nine hundred dollars (US
$1,858,900.00). The first two (2) fully creditable and non-refundable payments
to DOCRO totaling five hundred, fifty thousand dollars (US $550,000.00) as
described in this section of the Agreement and in any attachment to this
Agreement are made to DOCRO for the conduct of the technology assessment portion
of this Agreement. The first payment to DOCRO shall be a fully creditable,
non-refundable advance payment of two hundred, fifty thousand dollars (US
$250,000.00) upon execution of this Agreement. The second payment to DOCRO shall
be a fully creditable, non-refundable payment of three hundred thousand dollars
(US $300,000.00) sixty (60) days after the date of execution of this contract.
The basis for these amounts and the dates for additional payments to be made by
LEXON to DOCRO are set forth in Attachment A. - Estimated Fees, Milestone and
Payment Schedule. Such payments shall be made by wire transfer to DOCRO's bank
account: People's Bank of Connecticut, Bridgeport, Connecticut - Bank Routing
Number ▇▇▇▇▇▇▇▇▇, Account Number 014-▇▇▇▇▇▇▇. The aggregate amount of the two
advance payments, five hundred, fifty thousand dollars (US $550,000.00), shall
be subtracted from the total payment due to DOCRO hereunder.
3.3. DOCRO shall ▇▇▇▇ LEXON for the remaining balance of one million, three
hundred eight thousand, nine hundred dollars (US $1,308,900.00) plus any
additional expenses approved by LEXON and incurred as described in Attachment A.
- Estimated Fees, Milestone and Payment Schedule for services rendered on this
contract shall be billed to LEXON according to Attachment A., such monies to be
used by DOCRO for the assay development portion of this Agreement. LEXON shall
reimburse DOCRO on a net fifteen (15) day basis, time commencing from submission
to LEXON of invoice and statement of work completed or expenses incurred. If
timely payment for invoiced fees is not made, in addition to other remedies,
DOCRO may impose and LEXON shall pay, a late payment charge equal to one and
one-half percent (1.5%) of the overdue amount each month.
--4 of 14--
3.4. DOCRO will notify LEXON in writing within five (5) working days from the
effective date if the estimated fees and expenses for this project exceed one
million, eight hundred, fifty-eight thousand, nine hundred dollars (US
$1,858,900.00) (Fee Cap), including expenses described in Attachment A. -
Estimated Fees, Milestone and Payment Schedule, but not including additional
expenses, in which case LEXON may terminate the Agreement. DOCRO shall provide
LEXON a written Project Description & Estimate (PDE) describing the new aspects
or tasks required to complete the project. The Fee Cap shall not include any
fees or expenses applicable to any meeting with any person or group other than
meetings with LEXON or with Dr. H.E. ▇▇▇▇▇▇▇▇▇ to review work performed and
planned related to the technology assessment and development of the telomerase
tumor marker technology.
3.5. DOCRO shall not initiate any work the cost of which shall exceed the Fee
Cap prior to obtaining LEXON's written approval of a PDE. A PDE shall describe
the aspects of the project to be performed by DOCRO, including a description of
the specific personnel and other resources needed to perform the new tasks of
the project, the time or schedule needed to complete such tasks, and a proposed
schedule for project related payments. The Fee Cap shall be increased by the
amount of any approved PDE.
3.6. DOCRO shall ensure that all charges are allocated accurately to the
activity or project for which such charges were incurred, and are supported by
documents. The nature and purpose of all invoiced items shall be identified in
the supporting documents.
3.7. DOCRO shall be paid for reasonable and necessary business expenses that are
incurred by DOCRO in the course of performing the obligations of this Agreement
as described in this Agreement. Such costs may include, (but are not limited
to), the following: computer research; laboratory expenses; long distance
telephone and telefacsimile charges; postage, printing and courier charges; and
travel expenses, (including the cost of transportation, meals and lodging).
LEXON shall compensate DOCRO fully for all travel and living expenses that are
not described in Attachment A. but that either are agreed to by LEXON and are
incurred for site visits to the premises of LEXON, any clinical investigator,
any laboratory investigator, or any other location that may be requested or are
required in order for DOCRO to fulfill its obligations described in this
Agreement.
3.8. The cost to prepare or obtain any reagent, material, or product by a third
party on behalf of DOCRO and LEXON shall be passed on to LEXON with an eighteen
percent (18%) additional ▇▇▇▇-up by DOCRO. However, any equipment, materials,
consumables, or non-telomerase specific reagent paid for by LEXON shall become
the property of DOCRO upon the termination of this AGREEMENT.
--5 of 14--
4.0 Confidential & Proprietary Information
4.1. DOCRO and LEXON hereby agree with respect to Confidential & Proprietary
Information: (1) to maintain the confidentiality of any Confidential &
Proprietary Information disclosed; (2) not to make any disclosure of proprietary
or confidential information to any third party; (3) not to use Confidential &
Proprietary Information except for the Purposes contemplated in this Agreement,
unless such further use is specifically authorized in writing by the party who
has title to the information; (4) to protect the other's Confidential &
Proprietary Information whether in storage or in use, with the same degree of
care as is exercised to protect its own against public disclosure (but in no
case with any less degree than reasonable care); and (5) not to disclose
Confidential & Proprietary Information to any personnel other than those for
whom such knowledge is essential for the purposes contemplated in this
Agreement, and such disclosure to them shall be made only under conditions of
strict confidentiality.
4.2. The obligations in this Article shall not apply to Confidential &
Proprietary Information that a party can show by previously existing
documentation: (a) is in the public domain on the date of this Agreement; (b)
comes into the public domain other than through that party's fault or
negligence; (c) is obtained lawfully from a third party with full rights of
disclosure; (d) was known already to that party at the date of receipt of the
information pursuant to this Agreement; (e) becomes known independently to that
party without making use of any of the other party's Confidential & Proprietary
information.
4.3. If this Agreement expires or is terminated, then a receiving party shall
promptly return all Confidential & Proprietary Information, together with all
copies thereof, except for the retention of one copy for archival purposes. Upon
a written request, the parties shall respectively provide an accounting for the
disposition of all such documents or specimens, including a written
certification attesting to return of all such confidential information. The
parties shall return such items regardless of any claims against one another.
4.4. No party shall make any press release or other public announcement
concerning the terms or execution of this Agreement without prior written
consent of the other parties, which shall not be withheld unreasonably.
4.5. If a disclosure of Confidential & Proprietary Information prohibited by
this Agreement is specifically required by law or by court order, any party will
notify the other parties of such required disclosure and, if so requested, will
execute all necessary documents and provide all reasonable assistance necessary
to defend the other party's lawful right to prevent or limit such disclosure.
The notifying party shall be entitled reasonable compensation for assisting in
such a defense.
5.0 Warranties & Certifications
5.1. DOCRO warrants that it shall make its best efforts to evaluate and
demonstrate that the
--6 of 14--
telomerase technology performs technically and clinically as claimed and
represented by LEXON and by Dr. H. E. ▇▇▇▇▇▇▇▇▇, University of Maryland,
Baltimore. By 25 June 2000, LEXON shall deliver to DOCRO a document containing
those claims and representations. However, DOCRO does not guarantee that the
current telomerase reagents or assay as run in DOCRO's laboratory will meet or
exceed the performance claims asserted by LEXON or by Dr. H. E. ▇▇▇▇▇▇▇▇▇.
5.2. DOCRO does not guarantee that the telomerase reagents and assay to be
developed by DOCRO under the terms of this Agreement shall meet or exceed the
claims of LEXON nor does DOCRO guarantee that the developed assay shall provide
sufficient technical or clinical performance characteristics nor sufficient
clinical sensitivity and specificity to warrant additional assay development or
subsequent clinical trials, including any trial intended for submission to the
U.S. Food and Drug Administration for LEXON to gain approval to market a
telomerase assay in the United States of America.
5.3. DOCRO certifies that all of its employees, agents and contractors are bound
by the provisions of this Agreement, that it has obtained written agreements
from such employees and agents that are consistent with the provisions of
Section 4.0 of this Agreement, and that it will obtain written agreements from
employees, agents and contractors who in the future will become associated with
the project contemplated in this Agreement.
5.4. DOCRO represents and certifies that it and its employees and agents have
all appropriate expertise, training, certifications, immunizations and equipment
to safely and lawfully handle any materials, perform any laboratory tests, or
enter into work areas which may be necessary for work performed under this
Agreement.
5.5. LEXON certifies that all of its employees, agents and contractors are bound
by the provisions of this Agreement, that it has obtained written agreements
from such employees and agents that are consistent with the provisions of
Section 4.0 of this Agreement, and that it will obtain written agreements from
employees, agents and contractors who in the future will become associated with
the project contemplated in this Agreement.
5.6. LEXON warrants that no danger, hazard, or the like is known with respect to
its PRODUCTS, other than those dangers known to be associated with infectious
blood samples.
5.7. LEXON and DOCRO warrant that the signatories to this Agreement are
authorized to execute this Agreement on behalf of the respective parties.
6.0 Modification of Agreement
6.1. No waiver or modification of this Agreement shall be valid, nor shall it be
offered or received in evidence in any proceeding, arbitration or litigation
between the parties arising out of or related to this Agreement, unless such
waiver or modification is in writing signed by authorized representatives of
both parties, particularly pointing out any provisions to be added, deleted, or
modified.
--7 of 14--
6.2. Unless expressly approved by the waiving party in accordance with Section
6.1., the failure of either party to enforce any provision of this Agreement
shall not be construed as a waiver or limitation of that party's rights to
subsequently enforce and compel strict compliance with every provision of the
Agreement. No waiver (express or implied) by either party of any breach of this
Agreement shall constitute a waiver of any other or subsequent breach.
7.0 Assignment
This Agreement shall be binding on and inure to the benefit of each party, its
successors or assigns. No assignment shall be made by either party without the
express written consent of the other party except that LEXON may assign this
agreement to a purchaser of substantially all of the assets of LEXON.
8.0 Independent Contractor Status
8.1. It is expressly stipulated, agreed and understood between the parties that
the business relationship between DOCRO and LEXON shall be that of independent
contractors, and does not constitute a partnership, joint venture, agency or
contract of employment.
8.2. No party shall have the authority to make any statements, representations
or commitments of any kind, or to take any action that shall be binding on the
other, except as provided for herein or authorized in writing by the parties to
be bound.
8.3. DOCRO shall be responsible solely for provision of personnel, equipment,
and supplies, and, subject to the terms of this Agreement, for payment of
DOCRO's costs, suppliers, employees and contractors. In no case shall any party
have the authority, or represent themselves as having the authority, to bind
legally any other in contract, debt or otherwise.
9.0 Notice
9.1. Any notice required under this Agreement shall be deemed given only upon
receipt of any letter or instrument sent by certified mail, return receipt
requested, postage prepaid by the sender, by overnight courier or by personal
delivery, unless prior notice is tenured by the sender that a signed telefaxed
response followed by confirmation by mail will satisfy the terms of this
provision.
If to DOCRO: If to LEXON:
------------ ------------
▇▇. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ▇▇. ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇.
President and Chief Executive Officer Medical Director
DIAGNOSTIC ONCOLOGY CRO, Inc. Lexon, Inc.
▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
--8 of 14--
9.3. From time to time either party, by written notice to the other in
accordance with this Section 9.0, may designate different or alternative
addresses or manners of delivery that shall become the effective or alternative
addresses, or manner of delivery, for such party or project as so designated.
10.0 Entire Understanding
This Agreement contains the complete understanding between the parties as to
conducting the technology assessment and technology development of the
telomerase tumor marker technology, but shall not as of the date of execution of
this Agreement, supersede the agreement between the parties dated 04 April 2000
and its extension dated 18 April 2000.
11.0 Severability
The terms of this Agreement are severable. If any term of this Agreement is held
invalid or unenforceable, the valid and enforceable portion of such term and the
remaining provisions of this Agreement will remain in full force and effect. The
remaining contract shall be interpreted consistently with the intent of the
parties with respect to the entire Agreement when the contract was executed.
12.0 Dispute Resolution
12.1. The parties agree that they will use their best efforts to resolve
amicably any dispute arising out of or relating to this Agreement. Any
controversy, claim or dispute that cannot be so resolved shall be settled by
final binding arbitration in accordance with the rules of the American
Arbitration Association and judgment upon the award rendered by the arbitrator
or arbitrators may be entered in any court having jurisdiction thereof. Any such
arbitration shall be conducted in Connecticut. Within one (1) month after the
commencement of the arbitration, each party shall select one person to act as
arbitrator, and the two arbitrators so selected shall select a third arbitrator
within one (1) month of their appointment. The Arbitration Period shall not
exceed three (3) months. Each party shall bear its own costs and expenses and an
equal share of the arbitrator's expenses and administrative fees of arbitration.
12.2. This Agreement shall be governed by and construed in accordance with the
laws of the State of Connecticut, without consideration of choice of law.
--9 of 14--
13.0. Headings
The headings contained in this Agreement are only for the convenience of the
parties and are not to be construed as a substantive provision and will not in
any manner affect the interpretation of this Agreement.
The parties execute this Agreement in accordance with all of the above terms and
conditions.
For Lexon, Inc.:
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇ Date: June 21, 2000
---------------------------- --------------------
Signature
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇, ▇▇., M.D.
Medical Director
For DIAGNOSTIC ONCOLOGY CRO, Inc.:
By: /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ Date: Friday, 09 June 2000
---------------------------- --------------------
Signature
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
President and Chief Executive Officer
--10 of 14--
ATTACHMENT A. - Estimated Fees, Milestones and Payment
Schedule - Lexon, Inc. - Telomerase Technology Assessment and
Development Project
Work to be Performed by DOCRO
1. DOCRO shall assess the technical and clinical performance characteristics
of the currently existing telomerase reagents (raw, partially purified, or
purified telomerase peptides or proteins (native or recombinant) and any
antibody thereto) provided to DOCRO by Dr. H.E. ▇▇▇▇▇▇▇▇▇, University of
Maryland, Baltimore, LEXON, or other source to determine if any telomerase
antigen is overexpressed in humans diagnosed with lung or other cancers
when compared to humans diagnosed with a disease other than cancer or to
apparently healthy, normal humans.
2. If one or more telomerase antigens meets the specifications in 1., above,
DOCRO shall develop and/or refine telomerase antibody and antigen reagents
with which DOCRO shall develop and then characterize a microtiter
plate-based enzyme immunoassay to determine the amount of that particular
telomerase antigen in the blood or other fluid matrix of human subjects.
3. DOCRO shall contract with, manage, oversee, and coordinate all other
contractors and subcontractors who provide any material prepared or service
required under the terms of this Agreement.
4. DOCRO shall provide to LEXON on a bi-weekly basis written reports of
DOCRO's progress and recommendations for the next segment of work to be
performed. LEXON must provide written notification to DOCRO within
forty-eight (48) hours of the issuance of the report if LEXON desires DOCRO
not to perform the work that DOCRO recommends in the report.
5. DOCRO shall provide to LEXON a written report summarizing DOCRO's findings
and activities upon DOCRO's completion of the technology assessment portion
of this Agreement and upon termination of this Agreement.
--11 of 14--
A. ESTIMATED Milestone and Payment Schedule:
ESTIMATED MILESTONE Payment Made by Lexon
Milestone Completion Date and Received by DOCRO
1. LEXON and DOCRO EXECUTE CONTRACT/First Payment 12 June 2000 US $ 250,000.00
2. DOCRO hires ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, Ph.D. as Project Director 14 June 2000
3. Project Meeting with ▇▇. ▇.▇. ▇▇▇▇▇▇▇▇▇ to Launch Project 16 Jun 2000
3. Transfer of portion of telomerase peptides, proteins, and antibodies 25 Jun 2000
from ▇▇. ▇▇▇▇▇▇▇▇▇'▇ laboratory to DOCRO's laboratory
5. Laboratory Work at DOCRO commences and continues through project 25 Jun 2000
a. Adds first then second bench staff personnel 17 Jul 2000
b. Interview and selection of contractor(s) for development and 17 Jul 2000
Production of peptides and polyclonal and monoclonal antibodies
c. Initiate purification of native telomerase 21 Jul 2000
d. Acquire fresh frozen tumor and clinical sample sets from ONGOING
colorectal cancer patients
e. Characterize reagents produced by ▇▇. ▇▇▇▇▇▇▇▇▇ or other source 12 Aug 2000 US $ 300,000.00
- chromatography, electrophoresis/blotting, etc.
f. Testing clinical sample sets (cancer, normal, benign) ONGOING
g. Initiate expression cloning of telomerase 14 Sep 2000
6. DOCRO and contractor(s) prepare peptides for Mab and Pab contractor(s) 28 Jul 2000
7. DOCRO completes selection and purification of native/recombinant 30 Nov 2000
telomerase proteins, ships sufficient quantities to Mab and Pab contractor(s)
8. DOCRO receives first bleeds of Pab's to peptides; purify/test 13 Oct 2000
--12 of 14--
9. DOCRO receives second bleeds of Pab's to peptides; purify/test 03 Nov 2000 US $ 400,000.00
DOCRO receives first Mab's to peptides; purify/test
10. DOCRO receives third bleeds of Pabs to peptides; purify/test 17 Nov 2000
11. DOCRO optimizes EIA sandwich assay using peptide antigen(s) 26 Jan 2001 US $ 400,000.00
and antibodies thereto, then test clinical samples
11. DOCRO receives first bleeds of Pab's to proteins; purify/test 09 Feb 2001
12. DOCRO receives second bleeds of Pab's to proteins; purify/test 23 Feb 2001
DOCRO receives first Mab's to proteins; purify/test
12. DOCRO optimizes EIA sandwich assay for the form of telomerase 27 Apr 2001 US $ 400,000.00
antigen overexpressed in lung or other cancers cancer and tests clinical
samples and compares results with those from EIA using peptide anitgens
12. DOCRO issues written report of findings and recommendations to LEXON 25 May 2001 US $ 108,900.00
13. LEXON makes GO/NO GO decision 29 June 2001
------------------------------------------------------------------------------------------------------------------------------------
TOTAL 13 MONTHS US $1,858,900.00
Comments:
Item 7. - This assumes the concentration of telomerase is greater than 50
microgram per gram of lung cancer tissue. If this minimum concentration is not
achieved, this milestone will depend solely upon either peptide antigen or
recombinant telomerase protein produced by/for DOCRO or Dr. H.E. ▇▇▇▇▇▇▇▇▇.
Item 12. - This milestone will be completed, most likely using peptide
polyclonal antibodies.
--13 of 14--
TELOMERASE Development Project
Lexon Telomerase Proposed Budget
CONFIDENTAL DETAILED INFORMATION
TOTAL - LABOR, LAB, AND MATERIALS - BILLABLE $ 1,858,900
--14 OF 14--